Skip to search formSkip to main contentSkip to account menu

darifenacin hydrobromide

National Institutes of Health

Related topics

Related topics

4 relations
24 HR darifenacin 15 MG Extended Release Oral Tablet24 HR darifenacin 15 MG Extended Release Oral Tablet [Enablex]darifenacin

Narrower (1)

Enablex

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Development and Evaluation of a (SEDDS) Self - Emulsifying Drug Delivery System for Darifenacin Hydrobromide
Background: The formulation and development of new chemical entities has the major challenge of low solubility. A fraction of… 
2018
2018
Preparation and Evaluation of Darifenacin Hydrobromide Loaded Nanostructured Lipid Carriers for Oral Administration
53 Preparation and Evaluation of Darifenacin Hydrobromide Loaded Nanostructured Lipid Carriers for Oral Administration Ali k. Ala… 
2012
2012
Identification and structural elucidation of two process impurities and stress degradants in darifenacin hydrobromide active pharmaceutical ingredient by LC-ESI/MS(n).
The present study describes the identification and characterization of two process impurities and major stress degradants in… 
2012
2012
Development and validation of RP-UPLC method for the determination of darifenacin hydrobromide, its related compounds and its degradation products using design of experiments.
2011
2011
Comparative Analysis of the Effects of Antimuscarinic Agents on Bladder Functions in Both Nonhuman Primates and Rodents
Both the physiological role of muscarinic receptors for bladder function and the therapeutic efficacy of antimuscarinic agents… 
2009
2009
Darifenacin hydrobromide
In the title compound {systematic name: (S)-3-[(aminocarbonyl)diphenylmethyl]-1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl… 
2009
2009
M(1) and M(3) muscarinic receptors are involved in the release of urinary bladder-derived relaxant factor.
2008
2008
Differential roles of M2 and M3 muscarinic receptor subtypes in modulation of bladder afferent activity in rats.
Review
2006
Review
2006
The Clinical Pharmacokinetics of Darifenacin
Darifenacin hydrobromide is a selective muscarinic M3 receptor antagonist that is indicated for use in treatment of overactive… 
2006
2006
Anticholinergika bei überaktiver Blase
ZusammenfassungAnticholinergika wirken in der Behandlung der überaktiven Blase durch Blockade von Muskarinrezeptoren, von denen 5… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)